Fig. 9: PFS with estrogen receptor and TNF/IFN gamma gene sets.
From: Determinants of response to CDK4/6 inhibitors in the real-world setting
a Genes associated with longer PFS as identified by univariate Cox Proportional Hazards Regression on each of the treatment cohorts. −Log10 p values from the AI and the FUL cohort are shown on the x-axis and the y-axis, respectively. Data are filtered by HR < 1, p value ≤ 0.1 (AI cohort) or p value ≤ 0.05 (fulvestrant cohort). b Estrogen response early gene set is associated with longer PFS as revealed by GSEA on combined cohort. c Bubble plot showing differential enrichment for gene sets between AI and fulvestrant treated cohorts. d Heatmap using genes from estrogen response module on gene expression data from pretreatment biopsies in the AI-treated cohort. e K-M plot showing PFS difference between high and low average expression values of this estrogen response gene module in the AI treated cohort. p < 0.001 by log rank test. f, g K-M plots showing survival difference between low and high average gene expression groups of the estrogen response gene module on the combined (f) or fulvestrant (g) treated cohorts. p < 0.001 and p = 0.55, respectively, by log rank test. h GSEA plot showing enrichment of genes in the TNF signaling via NFKB gene set. i, j Heatmap and K-M plot showing gene expression pattern of the TNF-IFN gamma gene module and its power in stratifying patients on the fulvestrant treated cohort using gene expression data from the pretreatment biopsies. p = 0.0012 by log rank test.
